PIQUR Therapeutics AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 2011-08-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.piqur.com
Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 9
- Registration Number
- NCT03127020
- Locations
- 🇩🇪
Medizinische Klinik und Poliklinik III, Munich, Bavaria, Germany
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
- First Posted Date
- 2017-04-19
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- PIQUR Therapeutics AG
- Registration Number
- NCT03120000
- Locations
- 🇫🇷
Aix-Marseilles Université, Marseille, France
🇫🇷Service de Neurology CHRU de Nancy, Nancy, France
🇫🇷Hôpital Pitié-Sâlpétrier,, Paris, France
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 10
- Registration Number
- NCT02850744
- Locations
- 🇨🇭
University Hospital Zurich, Neurology, Zurich, Switzerland
PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 41
- Registration Number
- NCT02723877
- Locations
- 🇪🇸
Hospital Universitarsi Vall d'Hebron, Barcelona, Catalan, Spain
🇪🇸Insitut Català d´Oncologia, Barcelona, Spain
🇪🇸Fundación Instituto Valenciano de Oncología, Valencia, Spain
PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 21
- Registration Number
- NCT02669511
Study of Oral PQR309 in Patients With Advanced Solid Tumors
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 70
- Registration Number
- NCT02483858
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
Open-Label, Non Randomized Phase 2 Study With Safety Run-In
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 53
- Registration Number
- NCT02249429
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇧🇦University Clinical Center Republic of Srpska, Banja Luka, Bosnia and Herzegovina
🇧🇦University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 28
- Registration Number
- NCT01940133
- Locations
- 🇨🇭
University Hospital Basel, Basel, Switzerland